Latest market price
144.85
+0.51+0.35%
OverviewShort InterestFilings
PTGXQT66Protagonist Therapeutics, Inc.·NASDAQ
144.85+0.35%
TA
Loading chart...
Screen all →
TGTX+5.34%$61.18TXG-14.03%$70.11CAI-5.01%$34.33PCVX-0.93%$62.03KRYS+2.38%$332.29SYRE-2.43%$96.56MDGL-0.31%$430.36IBRX-5.15%$8.29
Snapshot
Index—P/E140.63EPS (ttm)1.03Insider Own6.86%Shs Outstand64.71MPerf Week4.64%
Market Cap9.37BForward P/E—EPS next Y-0.39Insider Trans-10.02%Shs Float52.89MPerf Month4.07%
Enterprise Value8.60BPEG11.54EPS next Q2.50Short Float19.47%Perf Quarter9.50%
Income84.00MP/S33.36EPS this Y—Short Ratio16.27Perf Half Y47.25%
Sales281.00MP/B11.13EPS next Y-108.29%ROA9.36%Short Interest10.30MPerf YTD65.85%
Book/sh13.01P/C11.97EPS next 5Y12.19%ROE12.03%52W High160.81 -9.92%Perf Year88.88%
Cash/sh12.10P/FCF71.01EPS past 3/5Y—ROIC6.74%52W Low75.44 92.01%Perf 3Y928.03%
Dividend Est.—EV/EBITDA98.84Sales past 3/5Y19.43% 9.67%Gross Margin99.86%Volatility3.00% 3.93%Perf 5Y367.86%
Dividend TTM—EV/Sales30.60EPS Y/Y TTM47.67%Oper. Margin20.69%ATR (14)5.25Perf 10Y558.71%
Dividend Ex-Date—Quick Ratio21.71Sales Y/Y TTM33.81%Profit Margin29.40%RSI (14)57.91Recom2.00
Dividend Gr. 3/5Y—Current Ratio21.71EPS Q/Q516.36%SMA203.83%Beta1.16Target Price177.25
Payout0.00%Debt/Eq0.01Sales Q/Q3450.00%SMA501.34%Rel Volume0.50Prev Close144.34
Employees141LT Debt/Eq0.01EarningsNov 05SMA20024.20%Avg Volume648.20KPrice144.85
IPO DateAug 11, 2016Option/ShortYes / YesEPS/Sales Surpr.3.46% 7.46%Net Debt/EBITDA-8.90Volume322,552Change0.35%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-12-26ReiteratedUBS$184
Sep-01-26ReiteratedBMO CapitalOutperform$178 → $190
Sep-01-26ReiteratedBarclaysOverweight$153 → $180
Aug-31-26ReiteratedHC Wainwright & Co.Buy$117 → $170
Aug-17-26ReiteratedBMO CapitalOutperform$62 → $178
Aug-10-26ReiteratedTruist SecuritiesBuy$145 → $170
Aug-10-26UpgradeGoldman SachsNeutral → Buy$110 → $186
Aug-10-26ReiteratedWedbushOutperform$70 → $173
Aug-06-26ReiteratedBarclaysOverweight$151 → $153
Jul-17-26ReiteratedJohnson Rice$137 → $165
Latest News· Times ET
Oct-29-26
Oct-29-2611:02AM
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growthzacks.com
10:51AM
Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Termzacks.com
Oct-28-26
Oct-28-2610:56AM
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?zacks.com
Oct-27-26
Oct-27-2607:00AM
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026Yahoo
Oct-24-26
Oct-24-2611:45PM
Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounderseekingalpha.com
Oct-21-26
Oct-21-2607:07AM
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160Benzinga
Oct-19-26
Oct-19-2608:14AM
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)defenseworld.net
Oct-16-26
Oct-16-2602:59AM
Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX)defenseworld.net
Oct-15-26
Oct-15-2601:00PM
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Knowzacks.com
06:01AM
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth TodayBenzinga
Oct-08-26
Oct-08-2606:40AM
Protagonist Therapeutics (NASDAQ:PTGX): High Growth Momentum Meets Breakout SetupChartMill
Sep-29-26
Sep-29-2605:10AM
Johnson & Johnson: Strong Catalysts, But I'm Staying At HoldSeekingAlpha
Sep-24-26
Sep-24-2602:15AM
Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Reviewdefenseworld.net
Sep-23-26
Sep-23-2605:50AM
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth With a High-Quality Technical SetupChartMill
Sep-21-26
Sep-21-2601:00PM
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsightYahoo
Company

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2814643460—————
Cost of Goods Sold Incl. D&A0100—————
Gross Profit2814543460—————
Selling, General and Administrative Excl. Other48454333—————
Research and Development175159138120—————
Other Operating Expense1-111—————
Operating Income59-158253-94—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)26292715—————
Net Income Before Taxes84-129279-79—————
Income Taxes1140—————
Consolidated Net Income84-130275-79—————
Net Income From Continuing Operations84-130275-79—————
Net Income84-130275-79—————
EPS (Recurring)1.22-2.054.47-1.39—————
EPS (Basic, Before Extraordinaries)1.22-2.054.47-1.39—————
EPS (Diluted)1.03-2.054.23-1.39—————
EBITDA87-128282-76—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio140.63—9.13——————
Price To Sales Ratio34.02121.525.5121.78—————
Gross Margin100.0097.83100.00100.00—————
Operating Margin21.00-343.4858.29-156.67—————
Net Margin29.89-282.6163.36-131.67—————
Shares Outstanding66646257—————
Market Capitalization9,5605,5902,3931,307—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$173.98$140.69$107.41$74.12$40.83● Close Price0.00M6.64M13.28M19.91M26.55MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ali AsifChief Financial OfficerSep 30 '26Option Exercise23.7258,6291,390,735117,632Oct 02
Ali AsifChief Financial OfficerSep 30 '26Sale141.7858,6298,312,29459,003Oct 02
PATEL DINESH V PH DPresident and CEOSep 10 '26Sale144.107,2781,048,760522,968Sep 10
PATEL DINESH V PH DPresident and CEOSep 10 '26Option Exercise21.587,278157,059530,246Sep 10
PATEL DINESH V PH DPresident and CEOSep 09 '26Option Exercise21.5863,5481,371,366586,516Sep 10
PATEL DINESH V PH DPresident and CEOSep 09 '26Sale146.1863,5489,289,447522,968Sep 10
PATEL DINESH V PH DPresident and CEOSep 08 '26Sale145.8754,1747,902,361522,968Sep 10
PATEL DINESH V PH DPresident and CEOSep 08 '26Option Exercise21.5854,1741,169,075577,142Sep 10
PATEL DINESH V PH DPresident and CEOAug 11 '26Option Exercise21.5834,239738,878557,717Aug 12
PATEL DINESH V PH DPresident and CEOAug 11 '26Sale148.5234,2395,085,176523,478Aug 12
PATEL DINESH V PH DPresident and CEOAug 10 '26Option Exercise21.5865,7611,419,122589,239Aug 12
PATEL DINESH V PH DPresident and CEOAug 10 '26Sale149.1165,7619,805,623523,478Aug 12
Waddill William D.DirectorJun 23 '26Sale117.949,0001,061,4607,825Jun 25
Waddill William D.DirectorJun 23 '26Option Exercise16.549,000148,86016,825Jun 25
Waddill William D.DirectorJun 10 '26Option Exercise14.969,000134,64016,825Jun 11
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.